ME02202B - Jedinjenja pirolopirimidina kao inhibitori cdk4/6 - Google Patents

Jedinjenja pirolopirimidina kao inhibitori cdk4/6

Info

Publication number
ME02202B
ME02202B MEP-2015-157A MEP15715A ME02202B ME 02202 B ME02202 B ME 02202B ME P15715 A MEP15715 A ME P15715A ME 02202 B ME02202 B ME 02202B
Authority
ME
Montenegro
Prior art keywords
pyridin
pyrrolo
ylamino
diaza
cyclopentyl
Prior art date
Application number
MEP-2015-157A
Other languages
English (en)
Inventor
Yaping Wang
Christopher Thomas Brain
Young Shin Cho
John William Giraldes
Bharat Lagu
Julian Levell
Michael LUZZIO
Lawrence Blas Perez
Fan Yang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ME02202B publication Critical patent/ME02202B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (25)

1. Jedinjenje prema formuli (I)naznačen time, što:R1 predstavlja C3-7alkil; C4-7 cikloalkil po slobodnom izboru supstituisan sa jednim ili više supstituenta koji su odabrani iz grupe koju čine C1-6alkil i OH; fenil po slobodnom izboru supstituisan jednim supstitutentom koji je odabran iz grupe koju čine C1-6 alkil, C(CH3)2CN, i OH; piperidinil po slobodnom izboru supstituisan sa jednom ciklopropil grupom ili C1-6 alkilom; tetrahidropiranil po slobodnom izboru supstituisan sa jednom ciklopropil grupom ili C1-6 alkilom; ili biciklo[2.2.1]heptanil;gde A predstavlja CH ili N;gde R11 predstavlja vodonik ili C1-4 alkil;gde L predstavlja vezu, C(O), ili S(O)2;gde R2Y može da bude izabran iz grupe koju čineV je NH ili CH2;X je O ili CH2;W je O ili NH;gde m i n svaki za sebe predstavljaju 1, 2, ili 3 pod uslovom da m i n nisu oba 3;gde je svaka R2Y po slobodnom izboru supstituisana sa jednim do četiri supstituenata od kojih je svaki nezavisno odabran iz grupe koju čine: C1-3 alkil po slobodnom izboru substituisan sa jednim ili dva supstituenta od kojih je svaki nezavisno odabran iz grupe koju čine hidroksi, NH2, i -S-C1-3alkil; CD3; halo; okso; C1-3 haloalkil; hidroksi; NH2; dimetilamino; benzil; -C(O)-C1-3alkil po slobodnom izboru supstituisan sa jednim ili dva supstituenta od kojih je svaki odabran iz grupe koju čine NH2’ -SCH3 i NHC(O)CH3; - S(O)2-C1-4 alkil; i pirolidinil-C(O)-;gde R4 predstavlja, vodonik, deuterijum, ili C(R5)(R6)(R7); igde R5, R6, R7, R8, R9 i R10 svaki za sebe nezavisno predstavljaju H ili deuterijum; ili njena farmaceutski prihvatljiva so.
2.Jedinjenje formule (I-B) prema patentnom zahtevu 1, naznačen time, što L predstavlja vezu ili C(O); gde R2Y može da bude izabran iz grupe koju čine V je NH ili CH2; X je O ili CH2; W je O ili NH; gde m i n svaki za sebe nezavisno mogu da budu 1, 2, ili 3 pod uslovom da m i n m i n nisu oba 3; gde je svaka R2Y po slobodnom izboru supstituisana sa jednim do četiri supstituenata od kojih je svaki odabran iz grupe koju čine: C1-3 alkil po slobodnom izboru substituisan sa jednim ili dva supstituenta od kojih je svaki nezavisno odabran iz grupe koju čine hidroksi, NH2, i -S-C1-3alkil; CD3; C1-3 haloalkil; hidroksi; NH2; dimetilamino; benzil; -C(O)-C1-3alkil po slobodnom izboru supstituisan sa jednim ili dva supstituenta od kojih je svaki odabran iz grupe koju čine NH2’ -SCH3 i NHC(O)CH3; - S(O)2-C1-4 alkil; i pirolidinil-C(O)-; ili njena farmaceutski prihvatljiva so.
3. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što A predstavlja CH i R11 je vodonik; ili njena farmaceutski prihvatljiva so.
4. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što R4 predstavlja C(R5)(R6)(R7) i R5, R6, R7, R8, R9 i R10 mogu da predstavljaju vodonik, ili njenu farmaceutski prihvatljivu so.
5. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što R1 predstavlja C4-7 cikloalkil koji je po slobodnom izboru supstituisan jednom C1-6 alkil grupom, ili njena farmaceutski prihvatljiva so.
6. Jedinjenje prema bilo kojem od predhodnih patentnih zahteva, naznačen time, što je R2Y nesupstituisana ili njena farmaceutski prihvatljiva so.
7. Jedinjenje prema bilo kojem od patentnih zahteva 1-5 naznačen time, što R2Y predstavlja ili od kojih je bilo koja po slobodnom izboru supstituisana C1-3alkilom, ili njena farmaceutski prihvatljiva so.
8. Jedinjenje prema bilo kojem od patentnih zahteva 1-5 naznačen time, što R2Y predstavlja koja je po slobodnom izboru supstituisana C1-3 alkilom, ili njena farmaceutski prihvatljiva so.
9. Jedinjenje formule (I-C) u kojoj: R1 predstavlja ciklobutil, ciklopentil, cikloheksil, cikloheptil, gde je svaka od njih po slobodnom izboru supstituisana sa jednom metil,etil, ili OH; gde A predstavlja CH ili N; L može da predstavlja vezu, -C(O)-, ili S(O)2-; gde R2Y može da bude jedna iz grupe koju čine ili gde je svaka R2Y po slobodnom izboru supstituisana jednim ili dva supstituenta koji su nezavisno odabrani iz grupe koju čine halogen, metil, etil, ili okso; gde V predstavlja NH ili CH2; gde R4 predstavlja vodonik, deuterijum, ili C(R5)(R6)(R7); i R5, R6, R7, R8, R9 i R10 svaki za sebe nezavisno predstavljaju H ili deuterijum; ili njena ili njena farmaceutski prihvatljiva so.
10. Jedinjenje prema patentnom zahtevu 9, naznačen time, što A predstavlja CH; ili njena farmaceutski prihvatljiva so.
11. Jedinjenje prema patentnom zahtevu 10 naznačen time, što L predstavlja vezu ili -C(O)- i gde R4 predstavlja CH3; i R8, R9 i R10 mogu da budu H; ili njena farmaceutski prihvatljiva so.
12. Jedinjenje prema patentnom zahtevu 11 naznačen time, što R1 predstavlja ciklopentil; ili njena farmaceutski prihvatljiva so.
13. Jedinjenje prema patentnom zahtevu 1, naznačen time, što može biti odabrano iz grupe koju čine: 2-(5-(2,6-Diazaspiro[3.3]heptan-2-karbonil)piridin-2-ilamino)-7-ciklopentil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-(4-terc-Butil-fenil)-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Cikloheptil-2-[5-(2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-8-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 2-(5-(2,7-diazaspiro[3.5]nonan-7-karbonil)piridin-2-ilamino)-7-cikloheptil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-ciklopentil-2-[5-(8-metil-3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; metilamid 7-Ciklopentil-2-[5-((S,S)-2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-(3-terc-Butil-fenil)-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 2-(5-((1R,5S)-3-oksa-7,9-diazabiciklo[3.3.1]nonan-9-karbonil)piridin-2-ilamino)-7-ciklopentil-N,N-dimetil-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-[4-(Cijano-dimetil-metil)-fenil]-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-8-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1S,6R)-3,9-diaza-biciklo[4.2.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-3,9-diaza-biciklo[4.2.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,6-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(5’-okso-8-azaspiro[biciklo[3.2.1]oktan-3,3’-pirolidin]-1’-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-Ciklopentil-2[5-(1-okso-heksahidro-pirolo[1,2-a]pirazin-2-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,8-diazaspiro[4.5]dekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; dimetilamid 7-Ciklopentil-2-[5-((1S,6R)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 2-[5-(4-Okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7-fenil-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; i 7-cikloheksil-N,N-dimetil-2-(5-(4-okso-3,9-diazabiciklo[4.2.1]nonan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; ili njena farmaceutski prihvatljiva so.
14. Jedinjenje prema patentnom zahtevu 1, naznačen time, što može biti odabrano iz grupe koju čine: dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((S,S)-2,5-diaza-biciklo[2.2.1]heptan-2-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-((1S,5S)-3,6-diaza-biciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklobutil-2-[5-((1S,6R)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Cikloheksil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)- piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-6-metil-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,8-diaza-biciklo[3.2.1]oktan-3-karbonil)-4-metil-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; dimetilamid 7-Ciklopentil-2-[5-(3,9-diaza-biciklo[3.3.1]nonan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; 7-ciklopentil-N,N-dimetil-2-(5-(3-okso-1,4-diazabiciklo[3.2.2]nonan-4-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((1R,6S)-9-metil-4-okso-3,9-diazabiciklo[4.2.1]nonan -3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aS,6aR)-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aR,6aS)-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-cikloheptil-N,N-dimetil-2-(5-(cis-6-oksotetrahidro-1H-pirolo[3,4-c]piridin-5(6H,7H,7aH)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(cis-6-oksotetrahidro-1H-pirolo[3,4-c]piridin-5(6H,7H,7aH)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((3aR,6aS)-5-metil-1-oksoheksahidropirolo[3,4-c]pirol-2(1H)-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-((1R,3r,5S)-2’-okso-8-azaspiro[biciklo[3.2.1]oktan-3,5’-oksazolidin]-3’-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,8-diazaspiro[4.6]undekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamid; 7-ciklopentil-N,N-dimetil-2-(5-(2-okso-1-oksa-3,7-diazaspiro[4.5]dekan-3-il)piridin-2-ilamino)-7H-pirolo[2,3-d]pirimidin-6-karboksamide; dimetilamid 7-Ciklopentil-2-[5-((S)-2-okso-1-oksa-3,7-diaza-spiro[4.5]dec-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; i dimetilamid 7-Ciklopentil-2-[5-((R)-2-okso-1-oksa-3,7-diaza-spiro[4.5]dec-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline; ili njena farmaceutski prihvatljiva so.
15. Jedinjenje prema patentnom zahtevu 1, naznačen time, što 7-ciklopentil-N,N-dimetil-2-(5-((1R,6S)-9-metil-4-okso-3,9-diazabiciklo[4.2.1]nonan-3-il)piridin-2-ilamino)-7H-pirolo[2,32,3-d]pirimidin-6-karboksamid ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
16. Jedinjenje prema patentnom zahtevu 1, naznačen time, što dimetilamid 7-Ciklopentil-2-[5-(3,8-diazabiciklo[3.2.1]oktan-3-karbonil)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
17. Jedinjenje prema patentnom zahtevu 1, naznačen time, što dimetilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu ili njena farmaceutski prihvatljiva so.
18. Jedinjenje prema patentnom zahtevu 1, naznačen time, što metilamid 7-Ciklopentil-2-[5-((1R,6S)-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6-karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
19. Jedinjenje prema patentnom zahtevu 1, naznačen time, što metilamid 7-ciklopentil-2-[5-((1R,6S)-9-metil-4-okso-3,9-diaza-biciklo[4.2.1]non-3-il)-piridin-2-ilamino]-7H-pirolo[2,3-d]pirimidin-6- karboksilne kiseline ima sledeću formulu: ili njena farmaceutski prihvatljiva so.
20. Farmaceutska kompozicija koja obuhvata jedinjenje prema bilo kojem od predhodnih patentnih zahteva, ili njena farmaceutski prihvatljiva so, i farmaceutski prihvatljivi nosač ili ekscipijent.
21. Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u medicini.
22. .Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u lečenju raka.
23. Jedinjenje prema patentnom zahtevu 1 ili 9, za upotrebu u lečenju raka, naznačen time, što je odabrano iz grupe koju čine: mantle ćelijski limfom, multipli mijelom, rak dojke, ezofagealni kancer skvamoznih ćelija, liposarkom, T-ćelijski limfom, melanom, nesitnoćelijski rak pluća i rak pankreasa, folikularni karcinom štitaste žlezde, tumor mezenhimalnog porekla, fibrosarkom, rabdomiosarkom, tumor centralnog ili perifernog nervnog sistema, astrocitom, neuroblastom, gliom, švanom, melanom, seminom, teratokarcinom, osteosarkom, kseroderma pigmentozum, retinoblastom, keratoakatantom, i Kapošijev sarkom, karcinom bešike, dojke, debelog creva, bubrega, epidermis, jetre, pluća, ezofagusa (jednjaka), žučne kese, karcinom jajnika, pankreasa, stomaka, cerviksa, štitne žlezde, nosa, glave i jezika, prostate, i kože, leukemija, akutna limfocitna leukaemija, hronična limfocitna leukaemija, B-ćelijski limfom, difuzni krupnoćelijski B limfom, T-ćelijski limfom, Hodžkinov limfom, ne Hodžkinov limfom, limfom vlasastih ćelija, i Burkitov limfom, glioblastom multiforme, T ćelijski ALL, sarkomi i familijarni melanom.
24. Upotreba jedinjenja prema patentnom zahtevu 1 u proizvodnji leka za lečenje raka.
25. Jedinjenje formule (I) prema patentnom zahtevu 1, ili njena farmaceutski prihvatljiva so u kombinaciji sa jednim ili više drugih terapijskih sredstava za simultanu, odvojenu ili sekvencijalnu upotrebu u terapiji. EP 2 536 730 B1 REFERENCE KOJE SU NAVEDENE U OPISU Popis literature od strane podnosioca služi samo kao priručnik za čitaoca. Priručnik nije deo Evropske patent dokumentacije. Iako se posvećuje velika pažnja prevodu referenci, greške i propusti ne mogu biti izuzeti i EPO se odriče svake odgovornosti u tom smislu • WO 2007140222 A [0006] • WO 2009085185 A [0006] • WO 2008135232 A [0006] • US 20090203688 A [0006] • WO 2010020675 A [0134] [0267] [0274] • WO 2009067108 W [0260] • WO 2005097791 W [0279] • WO 2007040282 A [0303] • WO 2006137769 W [0362] • DE 102005030051 A1 [0638] [0650] [0670] Nepatentna literatura koja je navedena u opisu: • ORTEGA et al. Biochimica et Biophysica Acta-Reviews on Cancer, 2002, vol. 1602 (1), 73-87 [0002] [0003] [0004] • SHAPIRO. Journal of Clinical Oncology, 2006, vol. 24 (11), 1770-1783 [0002] [0003] • LUNDBERG et al. Molecular and Cellular Biology, 1998, vol. 18 (2), 753-761 [0002] • KAMB et al. Science, 1994, vol. 264 (5157), 436-440 [0002] [0004] • SHERR et al. Genes & Development, vol. 13 (12), 1501-1512 [0002] • AMIN et al. Archives of Pathology & Laboratory Medicine, 2003, vol. 127 (4), 424-431 [0003] • OUDAT et al. Modern Pathology, 2001, vol. 14 (1), 175A [0003] • BERGSAGEL et al. Immunological Reviews, 2003, vol. 194 (1), 96-104 [0003] • JIANG et al. Cancer Research, 1992, vol. 52 (10), 2980-2983 [0004] • AMOLD et al. Journal of Clinical Oncology, 2005 [0004] • SIRVENT et al. American Journal of Surgical Pathology, 2007, vol. 31 (10), 1476-1489 [0004] • BRAMBILLA et al. Journal of Pathology, 1999, vol. 188 (4), 351-360 [0004] • COWGILL et al. American Journal of Surgery, 2003, vol. 186 (3), 279-286 [0004] • GAZZERI et al. Oncogene, 1998, vol. 16 (4), 497-504 [0004] • DAILEY et al. Cytokine & Growth Factor Reviews, 2005, vol. 16 (2), 233-247 [0005] • ENGELMAN. Nature Reviews Cancer, 2009, vol. 9 (8), 550-562 [0005] • GARCIA-ECHEVERRIA. Purinergic Signalling, 2009, vol. 5 (1), 117-125 [0005] • GRAY-SCHOPFER et al. Cancer and Metastesis Reviews, 2005, vol. 24 (1), 165-183 [0005] • JOHN et al. Oncogene, 2009, vol. 28, S14-S23 [0005] • SHARMA et al. Nature Reviews Cancer, 2007, vol. 7 (3), 169-181 [0005] • MORIARTY K.J. et al. Bioorg Med Chem Lett, 2006, vol. 16, 5778-5783 [0006] • Remington’s Pharmaceutical Sciences. Mack Publishing Company, 1985 [0053] • STAHL; WERMUTH. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Wiley-VCH, 2002 [0053] • GREEN ; WUTTS. Protective Groups in Organic Synthesis [0114] • AMIN, H. M. ; MCDONNELL, T. J. ; MEDEIROS, L. J. ; RASSIDAKIS, G. Z. ; LEVENTAKI, V.; ; O’CONNOR, S. L. ; KEATING, M. J. ; LAI, R. Characterization of 4 mantle cell lymphoma cell lines – Establishment of an in vitro study model. Arch. Pathol. Lab. Med., 2003, vol. 127, 424-431 [0886]
MEP-2015-157A 2010-02-19 2011-02-17 Jedinjenja pirolopirimidina kao inhibitori cdk4/6 ME02202B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30624810P 2010-02-19 2010-02-19
US201161429372P 2011-01-03 2011-01-03
US201161429997P 2011-01-05 2011-01-05
PCT/EP2011/052353 WO2011101409A1 (en) 2010-02-19 2011-02-17 Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EP11707115.9A EP2536730B1 (en) 2010-02-19 2011-02-17 Pyrrolopyrimidine compounds as inhibitors of cdk4/6

Publications (1)

Publication Number Publication Date
ME02202B true ME02202B (me) 2016-02-20

Family

ID=44201966

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-157A ME02202B (me) 2010-02-19 2011-02-17 Jedinjenja pirolopirimidina kao inhibitori cdk4/6

Country Status (38)

Country Link
US (2) US8957074B2 (me)
EP (1) EP2536730B1 (me)
JP (1) JP5788415B2 (me)
KR (1) KR101812357B1 (me)
CN (1) CN102918043B (me)
AR (1) AR080198A1 (me)
AU (1) AU2011217286B2 (me)
BR (1) BR112012020922B1 (me)
CA (1) CA2790637C (me)
CL (1) CL2012002270A1 (me)
DK (1) DK2536730T3 (me)
DO (1) DOP2012000225A (me)
EA (1) EA022355B1 (me)
EC (1) ECSP12012111A (me)
ES (1) ES2548532T3 (me)
GE (1) GEP20146146B (me)
HN (1) HN2012001744A (me)
HR (1) HRP20151071T1 (me)
IL (1) IL221520A (me)
MA (1) MA34066B1 (me)
ME (1) ME02202B (me)
MX (1) MX2012009613A (me)
NI (1) NI201200135A (me)
NZ (1) NZ601754A (me)
PE (1) PE20121815A1 (me)
PH (1) PH12012501649A1 (me)
PL (1) PL2536730T3 (me)
PT (1) PT2536730E (me)
RS (1) RS54263B1 (me)
SG (1) SG183218A1 (me)
SI (1) SI2536730T1 (me)
SM (1) SMT201500265B (me)
TN (1) TN2012000413A1 (me)
TW (1) TWI503322B (me)
UA (1) UA108369C2 (me)
UY (1) UY33227A (me)
WO (1) WO2011101409A1 (me)
ZA (1) ZA201206079B (me)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
PL2315756T3 (pl) 2008-07-08 2015-02-27 Incyte Holdings Corp 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
CN103002911B (zh) 2008-09-26 2015-08-26 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011130232A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
CN103635189B (zh) 2011-07-01 2016-05-04 诺华股份有限公司 用于治疗癌症的含有cdk4/6抑制剂和pi3k抑制剂的联合治疗
JP2015502958A (ja) * 2011-12-09 2015-01-29 オンコメッド ファーマシューティカルズ インコーポレイテッド がんの処置のための併用療法
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
SMT202100451T1 (it) 2012-07-11 2021-09-14 Blueprint Medicines Corp Inibitori del recettore di crescita dei fibroblasti
WO2014022830A2 (en) 2012-08-03 2014-02-06 Foundation Medicine, Inc. Human papilloma virus as predictor of cancer prognosis
WO2014066328A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
EA032649B1 (ru) 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
HK1222766A1 (zh) 2013-03-15 2017-07-14 G1治疗公司 高效的抗赘生剂和抗增生剂
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
CA2928042C (en) 2013-10-25 2022-05-10 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
RU2671494C2 (ru) * 2014-05-28 2018-11-01 Шанхай Фокон Фармасьютикал Ко., Лтд Некоторые ингибиторы протеинкиназы
CN105294737B (zh) * 2014-07-26 2019-02-12 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
AU2015314851B2 (en) * 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
US9969719B2 (en) * 2015-03-11 2018-05-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
JP7011596B2 (ja) * 2015-12-02 2022-02-10 アストライア セラピューティクス， エルエルシー ピペリジニルノシセプチン受容体化合物
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017161253A1 (en) 2016-03-18 2017-09-21 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US10835535B2 (en) * 2016-05-07 2020-11-17 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
SG10202101055VA (en) * 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CA3040815C (en) 2016-10-20 2021-07-20 Steven Martin Evans Anti-proliferative agents for treating pah
WO2018081211A1 (en) * 2016-10-26 2018-05-03 Li George Y Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide
AU2017359333B2 (en) 2016-11-08 2024-03-21 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
EP3556758B1 (en) 2016-12-16 2024-07-17 Cstone Pharmaceuticals (Suzhou) Co., Ltd. 1,2-dihydro-1,6-naphthyridin-2-one derivatives as cdk4/6 inhibitors
EP3565558B1 (en) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN108794452B (zh) 2017-05-05 2021-05-28 上海时莱生物技术有限公司 具有激酶抑制活性的化合物、其制备方法和用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
EP3728228A1 (en) 2017-12-22 2020-10-28 Ravenna Pharmaceuticals, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
MX2020007312A (es) 2018-01-08 2021-01-08 G1 Therapeutics Inc Regimenes de dosificacion superior de g1t38.
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2019161224A1 (en) * 2018-02-15 2019-08-22 GiraFpharma LLC Heterocyclic compounds as kinase inhibitors
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
WO2019178239A1 (en) * 2018-03-13 2019-09-19 Board Of Regents, The University Of Texas System Methods for treatment of cancers with egfr activating mutations
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GEP20237548B (en) 2018-07-05 2023-10-10 Incyte Corp Fused pyrazine derivatives as a2a /a2b inhibitors
RS67557B1 (sr) 2018-08-24 2026-01-30 Pharmacosmos Holding As Unapređena sinteza 1,4-diazaspiro[5.5]undekan-3-ona
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CA3154278A1 (en) * 2018-10-12 2020-04-16 Corey Hopkins Phosphodiesterase inhibitors
CN111100128B (zh) * 2018-10-26 2022-09-06 广安凯特制药有限公司 一种瑞博西尼中间产品的合成方法及其中间体化合物
EP3902805A4 (en) * 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20200316064A1 (en) 2019-02-15 2020-10-08 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020168197A1 (en) 2019-02-15 2020-08-20 Incyte Corporation Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
MX2021013531A (es) 2019-05-05 2022-02-11 Qilu Regor Therapeutics Inc Inhibidores de cdk.
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4007602A1 (en) 2019-08-01 2022-06-08 Incyte Corporation A dosing regimen for an ido inhibitor
TW202115024A (zh) 2019-08-14 2021-04-16 美商英塞特公司 作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020364007A1 (en) 2019-10-11 2022-04-28 Incyte Corporation Bicyclic amines as CDK2 inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
CA3179692A1 (en) 2020-04-16 2021-10-21 Incyte Corporation Fused tricyclic kras inhibitors
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
ES3048084T3 (en) 2020-05-19 2025-12-09 Pharmacosmos Holding As Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
US12600717B2 (en) 2021-07-14 2026-04-14 Incyte Corporation Tricyclic compounds as inhibitors of KRAS
WO2023009438A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
WO2023036252A1 (zh) * 2021-09-08 2023-03-16 希格生科（深圳）有限公司 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023091746A1 (en) 2021-11-22 2023-05-25 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a kras inhibitor
TW202329937A (zh) 2021-12-03 2023-08-01 美商英塞特公司 雙環胺ｃｋ１２抑制劑
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CA3244187A1 (en) 2021-12-22 2023-06-29 Incyte Corporation SALTS AND SOLID FORMS OF AN FGFR INHIBITOR AND THEIR METHODS OF PREPARATION
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
TW202341982A (zh) 2021-12-24 2023-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｃｄｋ２抑制劑及其用途
EP4490151A1 (en) 2022-03-07 2025-01-15 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
EP4519267A4 (en) * 2022-05-05 2026-02-25 Beone Medicines I Gmbh HETEROCYCLIC COMPOUNDS, THEIR COMPOSITIONS AND ASSOCIATED PROCESSING METHODS
AR129675A1 (es) 2022-06-22 2024-09-18 Incyte Corp Inhibidores de cdk12 de aminas biciclicas
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024026290A1 (en) * 2022-07-25 2024-02-01 Cayman Chemical Company Incorporated NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS
CA3263134A1 (en) * 2022-07-29 2024-02-01 Cedilla Therapeutics, Inc. CDK2 INHIBITORS AND THEIR METHODS OF USE
WO2024220532A1 (en) 2023-04-18 2024-10-24 Incyte Corporation Pyrrolidine kras inhibitors
GEAP202616866A (en) 2023-04-18 2026-02-10 Incyte Corp 2-azabicyclo[2.2.1]heptane kras inhibitors
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US20250163079A1 (en) 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
US20250195536A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders
WO2026060143A1 (en) 2024-09-11 2026-03-19 Incyte Corporation Kras inhibitors
WO2026076207A1 (en) 2024-10-04 2026-04-09 Incyte Corporation Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
EP1485390B1 (en) 2002-03-07 2008-10-08 F. Hoffman-la Roche AG Bicyclic pyridine and pyrimidine p38 kinase inhibitors
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
CN101723891A (zh) 2003-02-10 2010-06-09 沃泰克斯药物股份有限公司 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法
US20050113379A1 (en) 2003-09-05 2005-05-26 Ping Ge Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
CA2546192C (en) 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
PE20051089A1 (es) * 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2007526906A (ja) 2004-03-05 2007-09-20 大正製薬株式会社 ピロロピリミジン誘導体
RS52545B (sr) 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
WO2005107760A1 (en) 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
WO2006008545A2 (en) 2004-07-22 2006-01-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives as protein kinase inhibitors
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
EP1846408B1 (en) 2005-01-14 2013-03-20 Janssen Pharmaceutica NV 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
AR054391A1 (es) 2005-06-20 2007-06-20 Astrazeneca Ab Procedimiento para la preparacion de 3,7- dihidroxi-1,5-diazaciclooctanos
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
WO2007030438A2 (en) 2005-09-06 2007-03-15 Pharmacopeia, Inc. Aminopurine derivatives for treating neurodegenerative diseases
GB0520164D0 (en) 2005-10-04 2005-11-09 Novartis Ag Organic compounds
US8338607B2 (en) 2005-10-06 2012-12-25 Nippon Soda Co., Ltd. Cyclic amine compounds and agents for pest control
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
WO2007075783A2 (en) 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2646429A1 (en) 2006-03-09 2007-09-13 Pharmacopeia, Inc. 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
KR20100108341A (ko) 2007-11-20 2010-10-06 브리스톨-마이어스 스큅 컴퍼니 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제
BRPI0821209A2 (pt) 2007-12-19 2019-09-24 Amgen Inc composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
UY31631A1 (es) 2008-02-06 2009-09-30 Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
WO2009115084A2 (de) 2008-03-20 2009-09-24 Schebo Biotech Ag Neue pyrrolopyrimidin-derivate und deren verwendungen
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
WO2011130232A1 (en) 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos

Also Published As

Publication number Publication date
CL2012002270A1 (es) 2012-10-26
EP2536730A1 (en) 2012-12-26
DK2536730T3 (en) 2015-09-28
NI201200135A (es) 2012-10-30
HK1176616A1 (en) 2013-08-02
AR080198A1 (es) 2012-03-21
CA2790637A1 (en) 2011-08-25
PT2536730E (pt) 2015-10-29
JP2013519707A (ja) 2013-05-30
BR112012020922B1 (pt) 2020-12-22
ZA201206079B (en) 2013-05-29
US20150099737A1 (en) 2015-04-09
DOP2012000225A (es) 2013-01-15
SI2536730T1 (sl) 2015-10-30
TN2012000413A1 (en) 2014-01-30
PH12012501649A1 (en) 2018-02-07
PE20121815A1 (es) 2013-02-03
EA201201161A1 (ru) 2013-03-29
UA108369C2 (uk) 2015-04-27
ECSP12012111A (es) 2012-09-28
US20130150342A1 (en) 2013-06-13
RS54263B1 (sr) 2016-02-29
TWI503322B (zh) 2015-10-11
CN102918043A (zh) 2013-02-06
WO2011101409A1 (en) 2011-08-25
MA34066B1 (fr) 2013-03-05
AU2011217286A1 (en) 2012-08-30
HRP20151071T1 (hr) 2015-11-06
HN2012001744A (es) 2015-08-24
UY33227A (es) 2011-09-30
EA022355B1 (ru) 2015-12-30
US8957074B2 (en) 2015-02-17
TW201130848A (en) 2011-09-16
AU2011217286B2 (en) 2014-06-19
BR112012020922A2 (pt) 2016-05-03
CN102918043B (zh) 2015-07-29
US9309252B2 (en) 2016-04-12
IL221520A (en) 2015-07-30
KR20130006625A (ko) 2013-01-17
CA2790637C (en) 2018-04-10
JP5788415B2 (ja) 2015-09-30
SG183218A1 (en) 2012-09-27
SMT201500265B (it) 2016-01-08
ES2548532T3 (es) 2015-10-19
PL2536730T3 (pl) 2015-12-31
MX2012009613A (es) 2012-09-12
GEP20146146B (en) 2014-08-25
KR101812357B1 (ko) 2017-12-26
EP2536730B1 (en) 2015-07-08
NZ601754A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
ME02202B (me) Jedinjenja pirolopirimidina kao inhibitori cdk4/6
JP2013519707A5 (me)
JP6263269B2 (ja) キナーゼ阻害剤及びその使用
US9828373B2 (en) 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
JP2024517693A (ja) ２－アミノベンゾチアゾール化合物及びその使用方法
ES2531465T3 (es) Derivados de pirimidinona, su preparación y su utilización farmacéutica
JP2024532733A (ja) 複素環式化合物及び使用方法
ME02635B (me) Novi derivati pirola, postupak njihove priprave i farmaceutski pripravci koji ih sadrže
BR112020022201A2 (pt) análogos de rapamicina ligada a c40, c28, e c-32 como inibidores de mtor
JP2017222709A5 (me)
JP2023549055A (ja) 複素環式スピロ化合物及びその使用方法
JP2015511245A5 (me)
JP2019535664A5 (me)
JP2013500975A5 (me)
NZ610018A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2014008913A (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
JP2015508075A5 (me)
JP2012528828A5 (me)
JP2020527174A5 (me)
ME02922B (me) Novi derivati indolizina, postupak njihove proizvodnje i farmaceutske kompozicije koje ih sadrže
US12006320B2 (en) Heterocyclic derivatives as PI3K inhibitors
RU2014109748A (ru) Морфолино-замещенные производные бициклических пиримидинмочевины или карбамата в качестве ингибиторов mtor
AU2021373162A1 (en) Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof
CN112867715A (zh) 作为腺苷受体拮抗剂的5-氮杂吲唑衍生物
RU2023134860A (ru) Ингибиторы мутации her2